Nov 21, 2024 | GLP-1s, MedBen Rx, Wegovy, Weight loss drugs, Zepbound
Bariatric surgeries to treat obesity dropped 25.6% from 2022 to 2023, while prescriptions for GLP-1 drugs more than doubled during that period, according to a new study of privately insured Americans with obesity. However, those who opt for the surgery are...
Nov 11, 2024 | Genomics, MedBen Rx, Nutrigenomics, Pharmacogenomics
Genomic testing is revolutionizing precision medicine, offering unprecedented insights into how your body interacts with medications and nutrients. MedBen Rx offers pharmacogenomic and nutrigenomic tests that can help optimize your employees’ health care and...
Oct 29, 2024 | Client Report, Cost projections, Cost Savings, Drug costs, MedBen Rx, Prescription drugs, Rx Costs, Transparency, Trend
Health care costs in the United States are projected to see their steepest rise in over a decade during 2025, with multiple industry analyses forecasting increases between 7% and 8% year-over-year (see table below). However, MedBen offers solutions that directly...
Jul 5, 2024 | Biosimilar, Cost Savings, Drug costs, Humira, Idacio, MedBen Rx, News, Rx Costs, Savings
The Food and Drug Administration is considering a change to its biosimilar policy that would greatly speed up their approval process – which, if enacted, would be a big win for MedBen Rx clients who are already reducing their prescription drug spend through...
Apr 1, 2024 | Benefits preservation, Comparative Effectiveness, Cost Savings, Drug costs, MedBen Rx, Pharmacies, Pharmacy Benefits Manager (PBM), Rx Costs, Savings, Specialty Drugs, Transparency
Employers are turning away from the “big three” pharmacy benefits managers to other PBMs that offer greater transparency and lower costs, says Wharton professor of health care management Lawton Robert Burns. As one of those alternatives, MedBen Rx is...
Mar 5, 2024 | Appropriateness Solutions, Comparative Effectiveness, Cost Savings, Drug costs, MedBen Rx, Rx Costs, Value
At January’s Benefits Advisory Conference, MedBen President & CEO Kurt Harden observed that when the Food and Drug Administration (FDA) evaluates a new drug to be approved for sale, it has to be safe and effective, but not necessarily superior to...
